Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Accumulated Expenses (2016 - 2024)

Historic Accumulated Expenses for Arcadia Biosciences (RKDA) over the last 11 years, with Q4 2024 value amounting to $962000.0.

  • Arcadia Biosciences' Accumulated Expenses fell 1403.04% to $962000.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $962000.0, marking a year-over-year decrease of 1403.04%. This contributed to the annual value of $962000.0 for FY2024, which is 1403.04% down from last year.
  • As of Q4 2024, Arcadia Biosciences' Accumulated Expenses stood at $962000.0, which was down 1403.04% from $1.1 million recorded in Q4 2023.
  • In the past 5 years, Arcadia Biosciences' Accumulated Expenses registered a high of $1.6 million during Q4 2021, and its lowest value of $962000.0 during Q4 2024.
  • In the last 5 years, Arcadia Biosciences' Accumulated Expenses had a median value of $1.4 million in 2022 and averaged $1.3 million.
  • As far as peak fluctuations go, Arcadia Biosciences' Accumulated Expenses skyrocketed by 1542.64% in 2020, and later crashed by 1849.96% in 2023.
  • Over the past 5 years, Arcadia Biosciences' Accumulated Expenses (Quarter) stood at $1.5 million in 2020, then grew by 7.86% to $1.6 million in 2021, then decreased by 14.51% to $1.4 million in 2022, then fell by 18.5% to $1.1 million in 2023, then dropped by 14.03% to $962000.0 in 2024.
  • Its Accumulated Expenses stands at $962000.0 for Q4 2024, versus $1.1 million for Q4 2023 and $1.4 million for Q4 2022.